대한임상검사과학회논문투고규정 학술지발행 1967년창간시명칭은 대한임상병리사회지 (Korean Journal of Medical Technologists, 1967년 1권 1994년 26권 ) 이며변경된명칭은 1995년 대한임상병리검사과학회지 (Korean Journal of the Clinical Laboratory Science, 1995년 27권 2003년 35권, ISSN 1229-2850), 2004 년 대한임상검사학회지 및 2014년 대한임상검사과학회지 (Korean Journal of Clinical Laboratory Science, Korean J Clin Lab Sci, 2004년 36권 현재, pissn 1788-3544, eissn 2288-1662) 이다. 1. 발행간기학술지는매년 3월말일, 6월말일, 9월말일, 12월말일에발행한다. 2. 목적과범위대한임상검사과학회지의궁극적목적은교수와임상병리사들사이에서공유되는임상병리검사학및관련된생명과학, 보건의료과학분야의연구활동을통해학술발전에기여하는것이다. 투고가능한분야는생화학, 면역학, 핵의체외기술학, 혈액학, 수혈학, 미생물학, 기생충학, 조직학, 세포학, 세포유전학, 분자유전학, 전기생리학, 공중보건이다. 3. 등재된데이터베이스대한임상검사과학회지는한국연구재단 (National Research Foundation of Korea, NRF) 의한국학술지인용색인 (Korea Citation Index, KCI) 데이터베이스에등재되어있다. 4. 접근성대한임상검사과학회의웹사이트는 http://www.kscls.or.kr/ 이다. 대한임상검사과학회지는개방된학술지임을천명한다. 온라인논문투고시스템 http://www.kjcls.org/ 를통해무료로논문을검색하거나인쇄할수있다. 5. 저작권논문이학술지에게재될될경우, 그저작권은학회에인계한다. 대한임상검사과학회는대한임상검사과학회지의저작권과디지털자료에대한전송권을소유한다. 6. 논문출판비용및구독료논문출판비용 ( 영문초록교정비, 심사비, 게재비 ) 은학회에서부담한다. 연회비납부회원은학회웹사이트를통해서무료로논문을열람할수있다. 연구출판윤리 1. 연구출판윤리 연구출판윤리는 국제표준출판윤리가이드라인 (http:// publicationethics.org/international-standard-editors-andauthors, Committee on Publication Ethics, 출판윤리위원회 1997년 ) 을준용한다. 2. 사람 ( 인간및인체유래물 ) 대상연구 사람 ( 인간및인체유래물 ) 대상연구는 사람대상의학연구윤리원칙 (http://www.wma.net/en/30publications/10policies/ b3, Declaration of Helsinki, 세계의사협회, 2008년 ) 이나 생명윤리와안전에관한법률 (http://irb.or. kr/, 보건복지부, 2013년 ) 에따른다. 3. 동물대상연구 동물대상연구는 동물보호법과실험동물에관한법률 (http:// www.mafra.go.kr/, 농림축산식품부, 2008 년 ; http://www. mfds.go.kr/, 식품의약품안전처, 2012년 ) 에따른다. 4. 연구부정행위 (Research misconduct) 연구부정행위는연구의고안, 연구수행, 연구결과의보고및발표등에서행하여질수있는위조, 변조, 표절, 삭제, 자기기만, 중복투고, 중복출판, 논문분할, 부당한논문저자표시등을말하며각각의내용은다음과같다. 1) 위조 (Fabrication): 존재하지않는데이터나연구결과를인위적으로만들어내서그것을기록하거나보고하는행위 2) 변조 (Falsification): 연구와관련된재료, 장비, 방법등을허위로조작하는것, 또는데이터나연구결과를바꾸거나삭제하는것을통해연구의내용이정확하게발표되지않도록하는행위 3) 표절 (Plagiarism): 다른사람의아이디어, 연구과정, 결과, 말등을적절한인용없이도용하는행위
4) 삭제 (Deletion): 원하는결과도출에장애가되는데이터를고의적으로제거하는행위 5) 자기기만 (Self-deception): 연구자들이편향된사고나예단에의해충분한검증없이무의식적으로실험데이타수집에주관을개입시키는행위 6) 중복투고 (Duplicate submission): 타학술지에게재되었거나투고중인논문을본학술지에투고하거나, 본학술지에게재되었거나투고중인논문을타학술지에투고하는행위 7) 중복출판 (Redundant publication): 인쇄된출판물이나전자매체를통해이미출판된논문을중복하여출판하는행위 8) 논문분할 (Paper partitioning): 기존에발표된논문의상당부분을새로운논문으로작성하여투고하는행위 9) 부당한논문저자표시 (Inappropriate listing of authors): 연구내용또는결과에대하여공헌또는기여를한사람에게정당한이유없이논문저자자격을부여하지않거나, 공헌또는기여를하지않은자에게감사의표시또는예우등을이유로논문저자자격을부여하는행위 5. 저자관계논문저자로나열한사람은 1) 연구의기본개념설정과연구의설계, 자료의분석과해석에공헌, 2) 논문을작성하거나내용의중요부분을변경또는개선하는데상당한공헌, 3) 출판될논문에최종적으로동의한사람으로상기조건을모두충족하는경우로한다. 6. 이해관계명시이해관계는저자 ( 또는저자의기관 ), 심사자, 편집인이금융적이거나개인적관계가있어원고작성, 심사와출판과정에영향을끼치는경우를말한다. 모든저자는 1) 금융적관련 ( 고용, 자문료, 주식보유 ), 2) 사적관련, 3) 연구경쟁, 4) 지적인관심사와같은이해관계를명시한다. 이해관계는감사의글에포함되어있어야한다. 7. 실험자료원본, 연구윤리관련서류 1) 편집위원회는저자에게해당기관의기관윤리위원회 (Institutional Ethics Committee, IEC; Institutional Review Board, IRB; Institutional Animal Care and Use Committee, IACUC) 의승인서또는피험자의서면동의서를요구할수있다. 2) 저자는논문작성에사용한실험자료원본, 연구윤리관련서류를논문출간시점으로부터 1년간보관하고있어야하며, 편집위원회의요청이있을경우이를제시하여야한다. 리위원회를구성하고운영하도록한다. 연구윤리에대한세부사항은별도의연구윤리위원회규정을따른다. 논문일반지침 1. 언어논문은국문혹은영문으로작성한다. 영문논문의경우영문교정증명서를복사하여표지파일에첨부한다. 2. 종류논문의종류는원저, 증례보고및편집위원회에서위촉한종설로한다. 3. 저자의자격저자는대한임상검사과학회회원 ( 정회원, 명예회원, 특별회원, 후원회원, 준회원 ) 이어야한다. 비회원인경우에는 1) 학회의회원과공동연구를하였을때, 2) 편집위원회의추천을받았을때회원이아니더라도투고할수있다. 4. 논문접수 1) 대한임상검사과학회 (http://www.kscls.or.kr/) 에 회원가입 하여야한다. 2) 대한임상검사과학회지온라인논문투고시스템 (http://www. kjcls.org/) 에 저자가입 하여야한다. 3) 논문은연중접수하며온라인논문투고시스템에접속하여투고한다. 4) 게재신청논문은저자점검표 (Author s checklist) 를작성하며저작권인계동의서 (Author s assurances and assignment of copyright), 영문교정증명서를온라인논문투고시스템에등록한다. 5) 학술지구독, 논문접수와관련된사항은대한임상검사과학회편집위원회 (Tel: 02-3291-5435, Fax:02-3291-5621, E-mail: office@kjcls.org, kamt@hanmailmet) 로문의한다. 논문세부지침 논문작성은 생의학학술지투고원고의통일양식 : 생의학논문원고의쓰기와편집 (http://www.icmje.org, 국제의학학술지편집인위원회, 2007년 ) 을준용한다. 8. 세부사항학회는연구부정행위를인지, 신고접수및조사할수있는연구윤 1. 구성 1) 논문분량은표, 그림을제외하고원저 A4용지 12페이지, 증례
보고 8페이지, 종설 16페이지이내로작성한다. 2) 논문은원칙적으로 Microsoft 워드프로세서로작성한다. (1) 국문논문의경우신명조체로작성한다. (2) 영문논문의경우 Times New Roman체로작성한다. (3) 글자크기는 10호, 줄간격은 1.5, 양쪽정렬로한다. (4) 상하좌우여백은기본으로설정되어있는것을그대로따른다. (5) 페이지의하단중앙에페이지번호를표기한다. 3) 표지, 본문, 표, 그림으로나누어작성한다. (1) 표지 (Cover): 원고종류, 연구분야, 영문제목, 국문제목, 영문저자, 국문저자, 영문소속, 국문소속, 영문교신저자연락처, 감사의글, 연구비지원, 이해관계 (2) 원고 (Manuscript) ( 저자관련모든내용을제외 ): 영문제목, 국문제목, 영문단축제목, 영문초록, 영문중심단어, 서론, 재료및방법, 결과, 고찰, 국문요약, 영문참고문헌, 그림설명 (Figure legends) (3) 표 (Table): 표는워드파일로작성 (4) 그림 (Figures): 그림은 ppt, jpg, gif 파일로작성 4) 원저 (Original article) 는서론, 재료및방법, 결과, 고찰의순으로작성한다. 5) 증례보고 (Case report) 는서론, 증례, 고찰의순으로작성한다. 6) 종설 (Review article) 은서론, 본론, 결론의순으로작성한다. 2. 띄어쓰기, 학술용어, 대문자, 소문자, 괄호, 전단어, 약어 1) 띄어쓰기는 국립국어원에제정한한글맞춤법통일안 (http:// www.korean.go.kr/) 을사용한다. 2) 학술용어는 대한의사협회에서발행한의학용어집 5판 (http:// kamje.or.kr/term) 을사용한다. 3) 본문문장중에영문의사용은가능한억제하고한글을사용하되, 영문을사용하여야할경우에는모두소문자로표기한다. 다만문장을시작하는곳에영문단어가올경우에는첫글자만대문자로표기한다. 4) 고유명사, 약품명, 단위, 적절한한글번역이없는의학용어등은영문으로직접표기한다. 한글만으로의미의전달이어려운의학용어는처음사용할때괄호 ( ) 안에원어를표기한후사용한다. 5) 괄호 ( ) 앞에영문이나숫자가올때는띄어쓰기를하고, 한글이올때는띄어쓰기를하지않고붙여서쓴다. ( 예 ) alkaline phosphatase (AP) ( 예 ) 대장균군 (coli-form bacteria) ( 예 ) 전혈구계산혹은혈구산정검사 (complete blood cell count, CBC) 6) 괄호 ( ) 안에괄호를넣을경우 ([ ]) 을사용한다. 7) 영문약어를처음사용할경우전단어를표기하고괄호 ( ) 안에 약어를제시하며, 다음부터는약어만사용한다. 단, 제목에는약어를사용하지않는다. 약어는다음예에따른다. ( 예 ) Clinical and Laboratory Standards Institute (CLSI) ( 예 ) body mass index (BMI) 3. 인명, 지명, 학명, 유전자명, 화학물질명, 상품명 ( 기기, 시약 ) 1) 인명, 지명등의고유명사는원어체로쓰며, 첫글자를대문자로표기한다. 2) 학명 ( 종, 속명 ) 은이탤릭체로하며, 처음표기시에는전체이름을풀어서표기하고 ( 예 : Escherichia coli), 그이후는속명이름을축약하여표기한다 ( 예 : E. coli). 속명이름을축약하여표기시다른균명과혼동이있으면축약하지않는다. 학명이아닌경우는이탤릭체로표기하지않는다. ( 예 ) 이탤릭체로표기하는경우 : E. coli, Parpovavirus, Simplexvirus ( 예 ) 이탤릭체로표기하지않는경우 : Coagulase-negative staphylococci, Hepatitis B virus ( 예 ) 이탤릭체와비이탤릭체를혼용하는경우 : Chlamydia spp., Achromobacter xylosoxidans subsp. xylosoxidans, Leptospira interrogans serovar icterohemorrhagieae, Ehrilichia sennetusu Nakazaki strain 3) 유전자명은이탤릭체 ( 일반적으로인간은대문자, 동물은첫자는대문자이고나머지는소문자, 바이러스는모두소문자 ) 로표기한다. 유전자생산물 ( 단백질 ) 명은정자체로표기한다. ( 예 ) 이탤릭체로표기하는경우 : BCR-ABL mutations, HER2 gene ( 예 ) 이탤릭체로표기하지않는경우 : BCR-ABL kinase domain, HER2-positive 4) 화학물질명은 미국화학회에서제공한 CAS 명명법 (Chemical Abstracts Service, http://www.cas.org/eo/regsys.html) 을사용한다. 약물은원칙적으로상품명피하고화학명또는일반명 ( 성분명 ) 으로표기한다. ( 예 ) 아세틸살리실산 (acetylsalicytic acid, aspirin) ( 예 ) 아스피린정 (Aspirin tablet) 5) 기기나시약에상품명을처음표기할경우괄호안에제조회사, 도시, 주 ( 州 ), 국가를제시한다. 상품명을의미하는 TM, 등은꼭필요한경우가아니면표기하지않는다. ( 예 ) Cell-Chex (Streck Incorporated, Omaha, NE, USA) ( 예 ) vancomycin (Sigma Chemical Company, St. Lousis, MO, USA) 6) 출처가표기된기기나시약을다시표기하는경우괄호안에제조회사만제시한다.
( 예 ) Cell-Chex (Streck Incorporated) ( 예 ) vancomycin (Sigma Chemical Company) 7) 초록에기기나시약을표기할때는제조회사와국가만을표기한다. ( 예 ) Cell-Chex (Streck Incorporated, USA) ( 예 ) vancomycin (Sigma Chemical Company, USA) 4. 단위, 통계기호, 성별, 연령, 대상, 회사, 기타 1) 숫자는아라비아숫자로표기하며, 천단위에쉼표 (,) 를사용한다. ( 예 ) 1,234 2) 단위표기는다음예에따른다. ( 예 ) 1명, 2개, 3개월 ( 예 ) 한명, 두개, 세번, 네칸, 다섯군데 ( 예 ) 200 예, 200례 ( 예 ) 비율 ( 모음 ), 백분율 ( ㄴ 받침 ), 검출률 ( 그외의받침 ) 3) 단위는 한국표준과학연구원에서제공하는국제표준단위 (International System of Units, http://www.kriss.re.kr/) 를사용함을권장한다. Liter 는대문자 L로표기한다. 수치와단위사이는띄어쓴다 ( 백분율, 온도, 각도는예외 ). ( 예 ) 9 ml ( ), 9mL ( ), 9 ml ( ), 9ml ( ), 9 ml ( ), 9ml ( ) ( 예 ) 9 L ( ), 9 mcl ( ), 9 microliter ( ), 9 ul( ) ( 예 ) 9 cells 10 3 / L ( ), 9 cells 10 3 /mcl ( ), 9 cells 10 3 /mm 3 ( ), 9 cells 10^3/mm^3 ( ) ( 예 ) Year (yr), Month (mon), Week (wk), Day (day), Hour (hr), Minute (min), Second (sec), 2 hr ( ), 2 hrs ( ), 3 min ( ), 3 mins (X), 4 sec ( ) ( 예 ) ph 7.0 ( ), PH 7.0 ( ) ( 예 ) 0.01 N HCl ( ), 0.01N HCl ( ) ( 예 ) 0.3 0.9 g ( ), 0.3-0.9 g ( ) ( 예 ) 10분간원심분리 (3,000 rpm, 1,500 RCF) (O), 10분간원심분리 (4,000 xg) (O), 10분간원심분리 (4,000 G) (O), 10분간원심분리 (4,000 g) ( ), 10분간원심분리 (4,000g) ( ) ( 예 ) 90%, 20 o C 4) 유의확률을나타내는통계기호 p는소문자, 이탤릭체로소수점이하 3자리까지표기한다. ( 예 ) p=0.002, p<0.001 5) 다른통계기호는정자체로표기한다. ( 예 ) r=0.975, R 2 =0.615, t=0.265, k=0.435 6) 성별은 M/F, 연령은 yr, 대상은 N으로표기한다. 7) 회사영문은 Corporation (Corp.), Company (Co.), Incorporated (Inc.), Limited (Ltd.) 등으로표기한다. 8) 본문제목에장, 절, 항, 목의번호 ( 예 : I, 1, 1), (1) ) 를표기하지않으나, 재료 ( 대상 ) 및방법, 결과의소제목에는번호 ( 예 : 1, 1) ) 를표기할수있다. 본문내용에서도번호쓰기를가급적억제한다. 9) 괄호 ( ) 안에쌍점 ( 콜론 [:] ) 과쌍반점 ( 세미콜론 [;] ) 은다음예에따른다. ( 예 ) (CBC: WBC, RBC, Hgb, Hct, MCV, MCH, MCH, Plt) ( 예 ) (heparin assay: heparin anti-xa; anti-factor Xa heparin; anti-fxa; anti-xa; Xa inhibition; heparin level; heparin activity) ( 예 ) (cell count: RBC, WBC; differential count: polymorphonuclear cell, lymphocyte, mononuclear cell) 5. 제목 (Title) 1) 제목은영문 20단어, 국문 70자이내로작성한다. 2) 출판시각면에기재할영문단축제목 (Running title) 을첨부한다. 3) 영문제목의경우명사, 형용사 ( 본동사, 부사 ) 는첫글자를대문자로표기하고, 전치사와관사는소문자로표기한다. 6. 저자 (Authors) 1) 저자는영문, 국문으로작성한다. 영문은이름과성, 국문은성과이름으로표기한다. 2) 저자수는 10명이내 ( 원저 10명이내, 증례보고 8명이내, 종설 4명이내 ) 로작성한다. 3) 저자수가 10명을초과할때에는공동저자의역할분담에대하여진술하고편집위원회의인정을받아야한다. 4) 영문은이름과성, 국문은성과이름으로표기하며다음예에따른다. (1) 1인저자인경우 : OOO (2) 2인저자인경우 : OOO and OOO (3) 3인이상의저자인경우 : OOO, OOO, and OOO ( (4) 저자영문명은 국립국어원에서제정한국어의로마자표기법 (http://www.korean.go.kr/) 사용함을권장한다. ( 예 ) Gildong Hong 홍길동 ( 권장, 이름에붙임표를사용하지않는것이원칙 ) ( 예 ) Gil-dong Hong 홍길동, Seong-il Hong 홍성일, Seon-gil Hong 홍선길 ( 권장, 이름음절구분이필요할때붙임표를사용하는것을허용 ) ( 예 ) Gil-Dong Hong 홍길동 ( 관행 ) ( 예 ) Gil Dong Hong 홍길동 ( 관행, 한국인은중간이름이없음 )
7. 소속 (Affiliations) 1) 소속은영문, 국문으로작성한다. 영문은부서와기관, 국문은기관과부서로표기한다. 2) 공동저자중소속이다른저자가있으면저자명뒤와소속명앞에윗첨자, 어깨번호를붙여서표기하며다음예에따른다. ( 예 ) OOO 1, OOO 1, and OOO 2 1 Department of Clinical Laboratory Science, Jeil University, Seoul, Korea 2 Department of Pathology, Usu Hospital, Cheongju, Korea 8. 교신저자의연락 (Corresponding author) 1) 교신저자의연락처는영문으로작성하며, 다음의예에따른다. ( 예 ) Corresponding author: OOO Department of Clinical Laboratory Science, Jeil University, Taepyeong-ro, Jung-gu, Seoul 01234, Korea Tel: 82-2-1122-3344 Fax: 82-2-1122-3349 E-mail: kimyoosin@juh.org 2) 이동전화번호는표기하지않는다. 9. 초록 (Abstract) 1) 초록은영문 250 단어이내에서하나의문단단락으로작성한다. 2) 비정형초록 (Unstructured abstract) 이지만배경, 방법, 결과, 결론의내용을포함하여야한다. 10. 중심단어 (Key words) 1) 중심단어는 국립의학도서관에서제공하는 Index Medicus 의의학주제용어 (http://www.nlm.nih.gov/mesh/mbrowser. html) 로표기할것을권장하며, 적절한해당용어가없을경우일반적인생의학용어로표기한다. 2) 중심단어는영문단어 5개이내로작성하며, 첫글자를대문자로표기한다. 11. 본문 (Main body) 1) 서론 (Introduction) 은연구목적이나혹은핵심이되는주제를취급한배경으로간결하게작성한다. 2) 재료및방법 (Materials and Methods) 은연구설계, 대상선정, 기기, 시약, 자료수집, 통계분석을통해재현이가능하도록구체적으로작성한다. 연구윤리와관련하여기관윤리위원회승인 ( 예 : IRB 심의결과서나 IRB 심의면제확인서에있는 IRB 승인번호 ) 받았음, 필요시서면동의서를받았음또는관련법률이 나지침에저촉되지않았음을명시한다. 3) 결과 (Results) 는연구결과에근거한객관적성적이나사실을명료하게작성한다. 표, 그림에있는내용을설명하며, 중요한경향및요점만작성한다. 4) 증례보고인경우 2-3) 항대신증례 (Case) 로대체하며실무에서얻은새로운것이나독특하거나보기드문사례를자세히작성한다. 5) 고찰 (Discussion) 은연구목적과연관하여최종결론 (Conclusion) 만을간략히작성한다. 연구결과에서중요하거나새로운소견을강조하고, 연관된다른논문자료와비교해석하며결과의적용, 제한점, 제언등을작성한다. 6) 요약 (Summary) 은영문초록에일치시키며국문 800자이내로작성한다. 7) 감사의글 (Acknowledgements), 연구비지원 (Funding), 이해관계 (Conflict of interest) 에대한명시가필요한것이있으면모두작성한다. 관련된내용이없으면 해당없음 (None) 으로작성한다. 12. 본문에문헌인용 (Citing references in the main body) 본문에문헌인용은 국립의학도서관추천양식 2판 (http:// www.nlm.nih.gov/citingmedicine, 국립의학도서관, 2007년 ) 을준용한다. 1) 본문에참고문헌을인용할경우인용순서에따라숫자를대괄호 [ ] 속에표기한다. 한참고문헌이본문에서계속인용될경우같은번호를사용한다. 2) 본문에다른저자가같은내용에서인용될때는인용순서에따라번호를붙인다. 대괄호 [ ] 속에숫자와쉼표 (,) 만사용하고, 쉼표뒤에는띄어쓰기를하지않는다. 3) 본문에문헌의인용은다음의예에따른다. (1) 참고문헌언급시 1개는 [1], 두개는 [1,2], 연속된 3개이상은 [2-5], 불연속적인 3개이상은 [1,3,5] 로표기한다. (2) 한문장의맨뒤에표기할경우 ( 일반적표기 ) ( 예 ) 하였다 [1], 보고되고있다 [1], 알려져있다 [1], 밝혀졌다 [1], 검출되었다고한다 [1] (3) 문장중간에표기할경우 ( 예 ) 와같이 [1], 보고된바있어 [1] (4) 국문논문에서저자명을언급할경우 ( 대괄호 [ ] 앞에국문이면붙여쓰기 ) ( 예 ) Hong[1] 의연구에서, Hong 과 Lee[2] 의연구에따르면, Hong 등 [3] 의연구에의하면 ( 예 ) 선행연구 [2-5] 에서밝혀진바와같이 ( 예 ) 면역표현형분석, 핵형분석, 유전형분석을병용하여수
행한다른연구 [6-8] 에서 (5) 영문논문에서저자명을언급할경우 ( 대괄호 [ ] 앞에영문이나숫자면띄어쓰기 ) ( 예 ) Hong [1], Hong and Lee [2], Hong et al. [3] 13. 참고문헌 (References) 참고문헌목록은 국립의학도서관추천양식 2판 (http://www. nlm.nih.gov/citingmedicine, 국립의학도서관, 2007년 ) 을준용한다. 1) 참고문헌은국문또는영문논문모두 References 라고표기한다. 2) 참고문헌은원저 25개이내, 증례보고 15개이내, 종설 50개이내로작성한다. 3) 참고문헌은영문으로작성한다. 영어이외의외국어로된참고문헌도영어로번역된것으로작성한다. 4) 참고문헌은본문에인용된번호순서대로작성한다. 5) 저자는성을먼저쓰고, 성뒤에이름첫글자를대문자로표기한다. ( 예 ) Henry JB (0), JB Henry (X), John B. Henry (X), John Bernard Henry (X) 6) 기관이나단체인저자는약어로도표기할수있다. ( 예 ) CAP, WHO. 7) 성격을달리하는저자는쌍반점 (;) 으로구분하여표기한다. ( 예 ) Henry JB; CAP; WHO. 8) 학술지에서저자가 2인이면 and 붙이지않고쉼표 (,) 로표기한다. 저자가 6인이하면전원을, 7인이상이면 6인만을기록하고, et al. 로생략한다. 9) 단행본에서저자가 2인이하면전원을, 3인이상이면 2인만을기록하고, et al. 로생략한다. 10) 제목은첫단어, 고유명사, 고유형용사 (Korean 등 ), 약어의경우만대문자로표기한다. 11) 학술지명은 국립의학도서관에서제공하는 Index Medicus 의공인약어 (http://www.ncbi.nlm.nih.gov/nlmcatalog/ journals) 로표기한다. 12) 학술지명은학술지가출판할당시의이름을사용하며, 학술지약어가없는경우전단어로표기한다. 13) 학술지발간일자의월이있는경우첫째 3글자 (Mar 등 ) 만약어로표기한다. 14) 학위논문 (Master s thesis, Doctoral dissertation) 은참고문헌으로인용하지않는다. 15) 학술대회발표자료 (Conference abstracts, Conference proceedings, Symposium) 는참고문헌으로인용하지않는다. 16) 학술지부록집의경우논문만참고문헌으로인용한다. 17) 학술지논문 (Journal article) 저자. 제목. 학술지. 연도 ; 권수 : 페이지수. 호수는생략가능 ( 예 ) 1. Yang BS, Park JY, Choi SG. Rapid detection of vancomycin-resistance enterococci in clinical sample from university hospital. Korean J Clin Lab Sci. 2013;45:16-20. ( 예 ) 1. Koo BK, Kim DE, Bang SH, Ryu KH, Kim HJ. Evaluation of the Nanopia P-FDP reagent kit for use in the STA-R EVOLUTION automated blood coagulation analyzer. J Lab Med Qual Assur. 2012; 34:63-68. ( 예 ) 1. Altier C. Genetic and environmental control of Salmonella invasion. J Microbiol. 2005;43(1):85-92. ( 예 ) 1. Roh JD, Kacena MA, Lopez-Soler RI, Coady CE, Troiano NW, Breuer CK. Glycolmethacrylate is superior to methylmethacrylate for histologic evaluation of biodegradable polymer scaffolds used for vascular tissue engineering. J Histotech. 2006;29: 245-250. ( 예 ) 1. Kaneko Y, Takeshita H, Mogi K, Nakajima T, Yasuda T, Itoi M, et al. Molecular, biochemical and immunological analyses of canine pancreatic DNase I. J Biochem. 2003;134:711-718. doi: 10.1093/jb/ mvg196 ( 예 ) 1. Payne DK, Sullivan MD, Massie MJ. Women s psychological reactions to breast cancer. Semin Oncol. 1996;23(1 Suppl 2):S89-97. 18) 서적 (Book) 저자. 도서명. 판수. 출판도시 : 출판사 ; 연도. p페이지수. 편저자, editor(s). 도서명. 출판도시 : 출판사 ; 연도. 장저자. 장제목. In: 편저자, editor(s). 도서명. 판수. 출판도시 : 출판사 : 연도. p페이지수. ( 예 ) 1. Sunheimer RL, Linda Graves L. Clinical laboratory chemistry. 1st edition. New York: Peaerson PLC; 2011. p34-40. ( 예 ) 1. Alberts B, Bray D, et al. Molecular biology of the cell. 3rd edition. New York: Garland publishing; 1994. p491-499. ( 예 ) 1. Clinical and Laboratory Standards Institute. Per-
formance standards for antimicrobial susceptibility testing; sixteenth informational supplement, M100- S16. Pennsylvania: Clinical and Laboratory Standards Institute; 2006. p96-97. ( 예 ) 1. Norman IJ, Redfern SJ, editors. Mental health care for elderly people. New York: Churchill Livingstone; 1996. p223-245. ( 예 ) 1. Ferreia-Gonzalez A, Wikinson DS. Establishing a molecular diagnosis laboratory. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods. 20th edition. Philadelphia: WB Saunders; 2001, p1333-1343. 19) 온라인자료 (Online source) 저자. 제목 [cited 인용연도날짜 ]. Available from: URL 최종접근시점. ( 예 ) 1. Korea Centers for Disease Control and Prevention. 2010 Disease web statistics system [cited 2012 January 16]. Available from: http://is.cdc.go.kr/ nstat/index.jsp. 20) 학술발표자료 (Abstract, Proceeding paper) 는참고문헌으로인용하지않는다. 14. 표 (Tables), 그림 (Figures) 1) 표와그림은영문으로작성한다. 표와그림을합하여 10개이내로작성하며문장의첫글자를대문자로표기한다. 표와그림의번호는 Table 1, Table 2, Fig. 1, Fig. 2 등의형식을취하며표와그림은모두순서대로정렬한다. 2) 본문에서인용되는순서에따라번호를붙이며, 표의제목은상단에, 그림의설명은하단에표기한다. 표의제목에는마침표를쓰지않고, 그림의설명에는마침표 (.) 를쓴다. 표나그림을본문에서인용할때에는다음예에따른다. ( 예 ) Table 1. Age and gender distribution of subjects ( 예 ) Fig. 1. Identification algorithm for NTM by PRA (PCR- RFLP). 3) 표의모든선은단선으로한다. 종선은긋지않으며횡선은가급적억제하나필요시 3-4개허용할수있다. 4) 표의각주는어깨글자설명, 약어설명의순으로하며, 어깨글자설명과약어설명사이에는반드시줄을바꾸어쓴다. 5) 어깨글자는위첨자로쓰되, 위치는단어의우측에 *,,,,,, **,, 의순서로사용하고숫자나알파벳은사용하지않는다. 여러어깨글자의설명은다음예에따른다. ( 예 ) *not tested. 6) 표에표시된약어는모두하단에설명을첨부한다. 약어설명은다음예에따른다. 표마다약어설명이중복될경우에는 See Table 1. 과같이표기한다. ( 예 ) Abbreviation: NG, no growth; SG, slightly growth. ( 예 ) See Table 1. Table 1. Prevalence of positivity for PTC by BRAF mutation in FINABC PTC (+) PTC (-) BRAF (+) BRAF (-) BRAF (+) BRAF (-) Cell paucity 5 5 1 91 Atypia 10 5 3 56 Total 15 10 4 147 Abbreviation: PTC, papillary thyroid carcinima; BRAF, B- type Raf kinase. 7) 그림이 2개이상의그림으로구성될때는 A, B 등으로표기하고, 다음의예와같이 A, B를각각설명하거나한꺼번에설명하고괄호안에서 A, B를기입할수도있다. 현미경사진일경우에는염색방법과배율을표기하여야한다. ( 예 ) Fig. 1. Results of papanicolaou s staining for liquidbased cytology (A, 200) and conventional smear (B, 200) in same adenocarcinoma cases. (A) A large number of macrophages was observed (arrows). (B) Macrophages cloud be observed. 논문심사절차 논문심사절차는 편집정책기술사항 (http://www.council science editors. org/, 과학편집인협의회, 2006 년 ) 을준용한다. 1. 전문가심사 (Peer review) 논문은 2인이상의심사위원이심사한다. 심사위원의견해는객관적이어야하고, 어떠한이해관계도없어야하며, 심사대상논문에대한비밀을지켜야한다. 논문심사결과는 게재가능 (accept), 수정후게재 (minor revisions), 수정후재심 (major revisions), 게재불가 (reject) 로판정한다. 심사소요기간은 2개월이내처리를원칙으로한다. 2. 편집위원심의논문은전문가동료에의한심사를거친후편집위원이심의한다. 이때편집위원은심사위원의지적사항에대한수정이미비한경우, 추가수정이필요한경우, 투고규정에맞지않는경우에재수정을
요청한다. 이후편집위원장이논문의게재여부를최종결정한다. 3. 논문수정저자는신규논문, 수정논문, 최종논문을온라인논문투고시스템에등록한다. 저자는심사위원의심사의견서와편집위원회의심사총평을확인하고, 심사지적사항에따라수정한내용을정리하여심사답변서에등록한다. ( 최종 ) 수정논문 1부에수정한부분을 적색표시 하여작성한후 ( 최종 ) 파일업로드에등록한다. 4. 논문유사도검색 (Similarity of articles) 학회는 한국연구재단검색서비스 (https://www.kci.go.kr/kciportal/), 한국과학기술정보연구원검색서비스 (http://scholar. ndsl.kr/index.do)", 한국교육학술정보연구원검색서비스 (http:// www.riss.kr/index.do) 등을통하여논문중복또는표절을점검하고있다. 5. 세부사항논문심사에대한세부사항은별도의논문심사규정을따른다. 부칙본규정은상임이사회의인준을받은날로부터시행한다. 본규정은 1999년 1월부터시행한다. 본규정은 2002년 11월부터시행한다. 본규정은 2005년 7월부터시행한다. 본규정은 2006년 2월부터시행한다. 본규정은 2008년 1월부터시행한다. 본규정은 2011년 1월부터시행한다. 본규정은 2013년 3월부터시행한다. 본규정은 2014년 5월부터시행한다. 본규정은 2015년 5월부터시행한다. 본규정은 2016년 1월부터시행한다.
Instruction for Authors Journal Publication The Korean Journal of Clinical Laboratory Science (KJCLS) is the official journal of the Korean Society for Clinical Laboratory Science. The ISO abbreviated title is Korean J Clin Lab Sci. It was launched in 1967. The primary title is Korean Journal of Medical Technologists (Volume 1, 1967 Volume 26, 1994). The changed title is Korean Journal of the Clinical Laboratory Science (Volume 27, 1995 Volume 35, 2003, ISSN 1229-2850) and Korean Journal of Clinical Laboratory Science (Korean J Clin Lab Sci, Volume 26, 2004 Present, pissn 1738-3544, eissn 2288-1662). KJCLS (http:// www.kjcls.org/) is published by the Korean Society for Clinical Laboratory Science (http://www.kscls.or.kr/). 1. Issue date KJCLS is published on the last day of every March, June, September, and December. 2. Aims and Scope The journal aims to contribute to a promotion of clinical laboratory science (formerly medical laboratory technology) through publication of research results with drawn from the domains of clinical laboratory science, related life science and healthcare science that are shared among scientists and technologists. The research areas are comprised of biochemistry, immunology, nuclear medicine in vitro technology, hematology, blood banking, microbiology, parasitology, histology, cytology, cytogenetics, molecular genetics, electrophysiology, and public health. 3. Bibliographical indexes and Databases All or part of the journal is indexed by KCI (Korea Citation Index). 4. Open and Free access KJCLS follows the open access journal. The full text is freely accessible from the web site (http://www. kjcls.org/journal/ archives.html). Digital files can be read, downloaded, and printed freely. 5. Copyrights All material published in the Journal will be copyrighted by Korean Society for Clinical Laboratory Science. 6. Article processing charge and Subscription fee Article processing charge (publication, review, and English correction fee) is free. The Subscription fee is 65,000 Korean Won (US $65). Research and Publishing Ethics Guidelines General Research and Publishing Ethics are decided by the Korean Society for Clinical Laboratory Science Research Ethic Committee. For policies on research and publication ethics not stated in these instructions, Guidelines on Good Publication Practice by the COPE (http://publicationethics. org/internationalstandards-editors-and-authors, Committee on Publication Ethics, 1997) can be applied. 1. Protection of human and animal rights 1) In the case of human experimentation, the authors must state in the text of their paper that the research has been carried out in accordance with the Declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3, World Medical Association, 2008) or the Enforcement Decree of Bioethics and Safety Act by the MHW (http:// irb.or.kr, Ministry of Health & Welfare, 2013). Consent must be obtained from each patient or subject after being given a full explanation of the purpose, nature and risk of all procedures used. In the case of animal experimentation, authors must state in the text the anesthetic procedures used in full, and all precautions they took to ensure that the animals did not suffer unduly during and after the experimental procedure. Authors must confirm that the experimental procedures were carried out in accordance with the Animal Project Act & Laboratory Animal Act by the MAFRA & MFDS (http://www.mafra. go.kr/, Ministry of Agriculture, Food and Rural Affairs,
2008; http://www.mfds.go.kr/ Ministry of Food and Drug Safety, 2012), in principle. 2) The Editorial Committee may ask for the submitting patients' consent or certification of approval by the Institutional Review Board. 2. Research misconduct 1) Fabrication: Artificial production of data or research results that do not exist or reporting and presenting such matters 2) Falsification: Manipulating the materials, apparatus, and methods related to the study falsely, or any conduct obstructing accurate presentation of the study results by replacing or deleting research results 3) Plagiarism: Stealing others' ideas, study results, products, saying, etc. without appropriate citation 4) Deletion: Intentional deleting of obstructive data in deriving the desired results 5) Self-deception: Unconsciously applying subjectiveness to research data collection due to biased thinking and premature predictions of the research 6) Duplicate submission: Submitting manuscripts that have been submitted to other journals or are in the course of such process to our journal or vice versa 7) Paper partitioning: Using a significant portion of an already published paper for preparing a new paper for submission to the journal 8) Inappropriate listing of authors: Not listing researchers having contributed to the study without reasonable cause, or listing unqualified people as authors without any contribution to the study as a courtesy or token of appreciation 9) Suggesting, forcing, or intimidating others to conduct the above violations 10) Intentional intervention of an investigation of the above violations by himself/herself or for others or harming or threatening to harm an informant 3. Authorship An author is considered as an individual who has made substantive intellectual contributions to a published study and whose authorship continues to have important academic, social, and financial implications. The following criteria for authorship: 1) substantial contributions to conception and design, acquisition, analysis, and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet criteria 1), 2), and 3) These criteria are applicable to those journals that distinguish the authors from other contributors. 4. Conflict of interest Conflict of interest exists when an author, reviewer, or editor has financial or personal relationships that inappropriately influence his/her actions. All authors should disclose their conflicts of interest, for example, consultancies, stock. Each author should certify the disclosure of any conflict of interest with his/her signature. Submission Guidelines The Korean Journal of Clinical Laboratory Science (KJCLS) must be written in Korea or English language. The manuscript types are comprised of original article, case report, and review article. Author (at least one author in case of multiple authors) of submitted manuscript be a member. Non-members can submit their manuscript upon the approval of the Editorial Committee. The author s name, affiliation, title, abstract, key words, corresponding author s contacts, tables, figures, and references should be specified only in English. This regulation is revised based on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals developed by the ICMJE (http://www.icmje.org, International Committee of Medical Journal Editors, 2007) and are supplemented ethical principles and rules for references. Other citation style not described in the instructions, the NLM Style, 2nd editions (http://www.nlm.nih.gov/citingmedicine, National Library of Medicine, 2007) can be applied. 1. Preparation of manuscripts Manuscript should be prepared in A4 paper with space of mm from top, bottom, right side and left side. Font (Simyeongjo or Times New Romans) size should be 10.0 points, row space 160%. The The length of manuscript should not exceed 12 pages (Original article is maximum 12, Case report is maxi-
mum 8, Review article is maximum 16). The format for word process program accepted is MS word DOC files, the language of the full text can be Korean and English. Medical terminology should be followed by the recent terminology book published by the Korean Medical Association. 2. Submission of manuscripts 1) Each author should upload 4 separate files: (1) Cover (article types, research areas, title, running title, authors, affiliations, corresponding author s contacts, acknowledgments, fund support, and conflicts of interest), (2) Manuscript (excluding the information regarding the authors and their affiliations, title, running title, abstract, introduction, materials and methods, results, discussion, summary, references, and figure legends), (3) Tables, (4) Figures. 2) Author s checklist, 3) Authors assurances and assignment of copyright. 3. Title The title should not exceed 20 words in English or 70 characters in Korean. A running title should be added if used heads in publication. 4. Authors The number of authors should not exceed 10 (Original article is maximum 10, Case report is maximum 8, Review article is maximum 4). 5. Abstract and Key words The unstructured abstract should not exceed 250 words in English without classification of category (background, methods, results, and conclusion). The key words should be not exceed 5 words. Use terms from the MeSH (http://www. nlm.nih.gov/mesh/mbrowser.html). 6. Main body The original article should be arranged in the following headings: introduction, materials and methods, results, and discussion. The case report should consist of introduction, case, and discussion. The review article should consist of introduction, main body, and conclusion. 1) Introduction: Cleary state the need of this study and main question or hypothesis of this study. Summarize the literature review or background in the area of the study. 2) Materials and Methods: Describe the study design, setting and samples, materials and measurements, procedure, analysis used. 3) Results: Describe the main results in a concise paragraph. This section should be the most descriptive. Note levels of statistical significance and confidence intervals where appropriate. 4) Discussion: Make discussion based only on the reported results. Conclusions should be written at the end of the discussion section. 7. Acknowledgments, Funding, and Conflict of interest This section should include a general acknowledgement, funding, and conflict of interest. 8. Reference citations in the main body Serially number the references in the order of citation in the main body with Arabic numerals in brackets (e.g. [1], [1,2], [2-5], [1,3,5]). 9. Reference list All references cited in the main body must appear in the Reference list. The total number of references may not exceed 25 (Original article is maximum 25, Case report is maximum 15, Review article is maximum 50). List all authors if there are less than or equal to six authors. List the first six authors followed by et al. if there are more than six authors. Journal titles should be described as a full name. If the reference is in Korean, then list the English version listed in the reference. 1) Journal article (e.g.) 1. Yang BS, Park JY, Choi SG. Rapid detection of vancomycin-resistance enterococci in clinical sample from university hospital. Korean J Clin Lab Sci. 2013; 45:16-20. (e.g.) 1. Koo BK, Kim DE, Bang SH, Ryu KH, Kim HJ. Evaluation of the Nanopia P-FDP reagent kit for use in the STA-R EVOLUTION automated blood coagulation analyzer. J Lab Med Qual Assur. 2012;34:63-68. (e.g.) 1. Altier C. Genetic and environmental control of
Salmonella invasion. J Microbiol. 2005;43(1):85-92. (e.g.) 1. Roh JD, Kacena MA, Lopez-Soler RI, Coady CE, Troiano NW, Breuer CK. Glycolmethacrylate is superior to methylmethacrylate for histologic evaluation of biodegradable polymer scaffolds used for vascular tissue engineering. J Histotech. 2006;29:245-250. (e.g.) 1. Kaneko Y, Takeshita H, Mogi K, Nakajima T, Yasuda T, Itoi M, et al. Molecular, biochemical and immunological analyses of canine pancreatic DNase I. J Biochem. 2003;134:711-718. doi: 10.1093/jb/mvg196 (e.g.) 1. Payne DK, Sullivan MD, Massie MJ. Women s psychological reactions to breast cancer. Semin Oncol. 1996;23(1 Suppl 2):89-97. 2) Book (e.g.) 1. Sunheimer RL, Linda Graves L. Clinical laboratory chemistry. 1st edition. New York: Peaerson PLC; 2011. p34-40. (e.g.) 1. Alberts B, Bray D, et al. Molecular biology of the cell. 3rd edition. New York: Garland publishing; 1994. p491-499. (e.g.) 1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement, M100- S16. Pennsylvania: Clinical and Laboratory Standards Institute; 2006. p96-97. (e.g.) 1. Norman IJ, Redfern SJ, editors. Mental health care for elderly people. New York: Churchill Livingstone; 1996. p223-245. (e.g.) 1. Ferreia-Gonzalez A, Wikinson DS. Establishing a molecular diagnosis laboratory. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods. 20th edition. Philadelphia: WB Saunders; 2001, p1333-1343. 3) Online source (e.g.) 1. Korea Centers for Disease Control and Prevention. 2010 Disease web statistics system [cited 2012 January 16]. Available from: http://is.cdc.go.kr/ nstat/index.jsp. 4) An unpublished thesis and dissertation are not permitted to be as a references. 5) Conference abstracts and conference proceedings are not permitted to be as a references. 10. Tables and Figures The number of tables and figures should not exceed 10. Each table and figure should be placed on a separate sheet. Number tables consecutively and supply a brief title at the top for each. Footnotes to a table are typed immediately below the table. The references marks are superscript small letters (*,,,,,, **,,, etc) with the footnotes arranged alphabetically by the superscripts. 11. Author s check list and Authors' assurances and assignment of copyright Authors should complete the author s check list and authors' assurances and assignment of copyright (http://www. kjcls.org/authors/ sub01.html) followed by signing, and submit these with the manuscript. It is should be submitted at Editorial Office. Manuscript cannot be published without this form. 12. On-line manuscript submission and review system Authors are requested to submit their papers electronically by through the On-line manuscript submission and review system (http://www.kjcls.org/submission/login.html). For more information on the Korean Society for Clinical Laboratory Science, please go to http://www.kscls.or.kr/. 1) Editorial Office: Korean Journal of Clinical Laboratory Science 5FL KAMT Bldg. 41, Jongam-Ro, Seongbuk-Gu, Seoul 02811, Korea Tel: +82-2-3291-5435 / Fax: +82-2-3291-5621 / E-mail: office@kjcls.org, kamt@hanmail.net 2) Please read all instructions before submitting. 3) The submission of manuscripts is processed (1) Manuscript type, Title, and Abstract, (2) Authors and Affiliations, (3) File upload, (4) Proof and Submit. Review Guidelines All review process will be done on-line manuscript submission and review system. Submitted manuscripts are usually reviewed by 2 or more experts (editors and reviewers) for blinded peer review. The peer reviewers shall evaluate the manuscript within 14 days
after review request. Review results of the fast-track manuscripts are notified within 1 month after the initial submission and regular-track manuscripts are decided within 2 months. The Korean Journal for Clinical Laboratory Science (KJCLS) Editorial Committee will make a final decision on the approval for publication of the submitted manuscripts and can request any further corrections, revisions, and deletions of the article text if necessary. Review and publication processes not described in the Instructions, will be incorporated into Editorial Policy Statements approved by the CSE (http://www.councilscienceeditors.org/, Council of Science Editors, 2006) can be applied. 1. Review evaluation 1) Suitability of the research topics (in agreement with the inauguration purpose of this Society) 2) Quality and uniqueness of the study 3) Research methods and the validity of logical development 4) Suitability of paper arrangement 5) Accuracy of references (citation in the main text, enumeration in references) 6) Academic and social contribution by the study results 7) Confirmity with the research ethics set by the Society 2. Review results 1) Accepted (Accepted for publication): The manuscript will be forwarded to the publisher without further corrections. 2) Minor revisions (Open to acceptance after the suggested revision): The author should address the comments from the reviewers, which will be confirmed by the reviewers before being sent to the publisher. 3) Major revisions (Resubmit after the suggested revisions): The author should address the comments from the reviewers and make the appropriate corrections for review by the reviewers. 4) Rejection (Not accepted for publication): (1) When 2 out of the 3 reviewers rejects the manuscript; (2) If the authors fail to submit a revised manuscript within 3 months, the final decision is made by the Editorial Committee.